BCRX
BIOCRYST PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$8.68
−0.23%Next report
Analyst consensus
- Next report date
- Nov 2, 2026
- EPS estimate
- $0.10
- Revenue estimate
- $165.4M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $0.30
- EPS estimate
- $0.15
- Revenue actual
- $218.3M
- Revenue estimate
- $183.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +357.0%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $22
- PT range
- $11 – $32
- Analysts
- 6
4 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $0.15 | $0.30 | Beat 94.55% | $218.3M |
| May 6, 2026 | $0.06 | -$0.03 | Miss -150.00% | $156.4M |
| Feb 26, 2026 | $0.07 | $1.12 | Beat 1500.00% | $406.6M |
| Feb 26, 2024 | -$0.24 | -$0.28 | Miss -16.67% | $93.4M |
| Nov 2, 2023 | -$0.25 | -$0.19 | Beat 24.00% | $86.7M |
| Aug 3, 2023 | -$0.25 | -$0.24 | Beat 4.00% | $82.5M |
| May 3, 2023 | -$0.30 | -$0.28 | Beat 6.67% | $68.8M |
| Feb 21, 2023 | -$0.19 | -$0.38 | Miss -100.00% | $79.5M |
| Nov 1, 2022 | -$0.32 | -$0.23 | Beat 28.13% | $75.8M |
| Aug 4, 2022 | -$0.36 | -$0.32 | Beat 11.11% | $65.5M |
| May 5, 2022 | -$0.39 | -$0.40 | Miss -2.56% | $49.9M |
| Feb 23, 2022 | -$0.31 | -$0.40 | Miss -29.03% | $47.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 2, 2026